U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H22N2OS.C4H4O4
Molecular Weight 442.528
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ACEPROMAZINE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.CN(C)CCCN1C2=CC=CC=C2SC3=CC=C(C=C13)C(C)=O

InChI

InChIKey=FQRHOOHLUYHMGG-BTJKTKAUSA-N
InChI=1S/C19H22N2OS.C4H4O4/c1-14(22)15-9-10-19-17(13-15)21(12-6-11-20(2)3)16-7-4-5-8-18(16)23-19;5-3(6)1-2-4(7)8/h4-5,7-10,13H,6,11-12H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C19H22N2OS
Molecular Weight 326.456
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Acepromazine a potent neuroleptic agent with a low order of toxicity, is of particular value in the tranquilization of dogs, cats and horses. Its rapid action and lack of hypnotic effect are added advantages. Acepromazine is a commonly used tranquilizer/sedative in dogs, cats, horses, and other animals. Veterinarians typically prescribe acepromazine to quiet agitated animals or use it as a part of an anesthetic protocol. It is important to note that when used alone, acepromazine is not an effective pain reliever and does little if anything to relieve a pet’s anxiety or fear. Acepromazine can also be used to treat motion sickness and nausea associated with car or plane rides. The mechanism by which acepromazine decreases a pet’s alertness is not fully understood. It is thought to block dopamine receptors in the brain or inhibit the activity of dopamine in other ways.

CNS Activity

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACEPROMAZINE MALEATE
Primary
PubMed

PubMed

TitleDatePubMed
Pulp histology after Er:YAG laser cavity preparation in subhuman primates--a pilot study.
2002 Aug
Combination therapy for footpad lesions in a captive Bengal tiger (Panthera tigris tigris).
2002 Dec
Effects of treatment with oxytocin, xylazine butorphanol, guaifenesin, acepromazine, and detomidine on esophageal manometric pressure in conscious horses.
2002 Dec
In vitro effects of oxytocin, acepromazine, detomidine, xylazine, butorphanol, terbutaline, isoproterenol, and dantrolene on smooth and skeletal muscles of the equine esophagus.
2002 Dec
Cardiopulmonary effects of xylazine and acepromazine in pregnant cows in late gestation.
2002 Dec
Effects of medetomidine-midazolam, acepromazine-butorphanol, and midazolam-butorphanol on induction dose of thiopental and propofol and on cardiopulmonary changes in dogs.
2002 Dec
Central sympathetic blockade ameliorates brain death-induced cardiotoxicity and associated changes in myocardial gene expression.
2002 Dec
The effects of xylazine, detomidine, acepromazine and butorphanol on equine solid phase gastric emptying rate.
2002 Jul
Murine models of chronic Pseudomonas aeruginosa lung infection.
2002 Jul
Evaluation of the perioperative stress response in dogs administered medetomidine or acepromazine as part of the preanesthetic medication.
2002 Jul
Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening.
2002 Jun
Effects of preoperative administration of ketoprofen on anesthetic requirements and signs of postoperative pain in dogs undergoing elective ovariohysterectomy.
2002 Nov 1
Reduced resident time and pharmacodynamic effects of acepromazine after subclinical multiple dosage in exercised thoroughbreds.
2002 Oct
Effects of acepromazine on capture stress in roe deer (Capreolus capreolus).
2003 Apr
Postoperative hypoxemia and hypercarbia in healthy dogs undergoing routine ovariohysterectomy or castration and receiving butorphanol or hydromorphone for analgesia.
2003 Feb 1
The sedative and behavioral effects of nalbuphine in dogs.
2003 Jul
A comparison of the analgesic effects of butorphanol with those of meloxicam after elective ovariohysterectomy in dogs.
2003 Jul
Hypotensive effect of push-pull gravitational stress occurs after autonomic blockade.
2003 Jul
Progressive changes in ophthalmic blood velocities in Beagles with primary open angle glaucoma.
2003 Mar
Changes in intraocular pressure and pupil size following intramuscular administration of hydromorphone hydrochloride and acepromazine in clinically normal dogs.
2003 Mar
Method for the noninvasive measurement of intraocular pressure in mice.
2003 Mar
Effects of acepromazine on renal function in anesthetized dogs.
2003 May
A comparison of preoperative tramadol and morphine for the control of early postoperative pain in canine ovariohysterectomy.
2003 Oct
Analysis of phenothiazine and its derivatives using LC/electrochemistry/MS and LC/electrochemistry/fluorescence.
2003 Sep 15
Orthologous gene-expression profiling in multi-species models: search for candidate genes.
2004
The effect of four anesthetic protocols on splenic size in dogs.
2004 Apr
Investigation of the effect of acepromazine on intravenous glucose tolerance tests in dogs.
2004 Aug
Systemic lidocaine infusion as an analgesic for intraocular surgery in dogs: a pilot study.
2004 Jan
Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically.
2004 Jul
NF-kappaB p50 facilitates neutrophil accumulation during LPS-induced pulmonary inflammation.
2004 Jun 9
Middle-latency auditory-evoked potential in acepromazine-sedated dogs.
2004 Mar-Apr
Effects of various anesthetic agents on laryngeal motion during laryngoscopy in normal dogs.
2004 Mar-Apr
An animal model for ultrasound lung imaging.
2004 May
Normal spatial and contextual learning for ketamine-treated rats in the pilocarpine epilepsy model.
2004 May
Sonographic features of drug-induced splenic congestion.
2004 May-Jun
Effect of meloxicam and carprofen on renal function when administered to healthy dogs prior to anesthesia and painful stimulation.
2004 Oct
Neuroleptanalgesia in wild Asian elephants (Elephas maximus maximus).
2004 Oct
Effects of doxapram HCl on laryngeal function of normal dogs and dogs with naturally occurring laryngeal paralysis.
2004 Oct
Intentional overdose of Large Animal Immobilon.
2004 Oct
Does the A-line ARX-lndex provide a reasonable assessment of anaesthetic depth in dogs undergoing routine surgery?
2004 Sep
Effects of ovariohysterectomy on canine blood neutrophil respiratory burst: a chemiluminescence study.
2004 Sep-Oct
Effects of chronic baroreceptor unloading on blood pressure in the dog.
2005 Apr
Therapeutic effects of Holmium-166 chitosan complex in rat brain tumor model.
2005 Feb 28
Overdose during chemical restraint in a black rhinoceros (Diceros bicornis).
2005 Jan
Laparoscopic nonanatomic hepatic resection employing the LigaSure device.
2005 Jan-Mar
Effects of acepromazine on pulmonary gas exchange and circulation during sedation and dissociative anaesthesia in horses.
2005 Mar
Muscle metabolic changes associated with long-term inhalation anaesthesia in the horse analysed by muscle biopsy and microdialysis techniques.
2005 Mar
Results of 24-hour ambulatory electrocardiography in dogs undergoing ovariohysterectomy following premedication with medetomidine or acepromazine.
2005 Mar 1
Analgesic efficacy of preoperative administration of meloxicam or butorphanol in onychectomized cats.
2005 Mar 15
Gamma scintigraphic evaluation of a miniaturized AERx pulmonary delivery system for aerosol delivery to anesthetized animals using a positive pressure ventilation system.
2005 Spring
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Acepromazine Maleate Injection may be given intravenously, intramuscularly or subcutaneously. The following schedule may be used as a guide to IV, IM or SC injections: Dogs: 0.25-0.5 mg/lb of body weight. Cats: 0.5-1 mg/lb of body weight. Horses: 2-4 mg/100 lb of body weight. 0.25 - 3 mg per kg body weight by oral administration.
Route of Administration: oral, intravenously, intramuscularly or subcutaneously
In Vitro Use Guide
The crude extract of Chlamydia pneumoniae induced the differentiation of monocytes into macrophages in 45 ± 5% of the cells. Acepromazine significantly reduced the mean percentage of differentiated cells: with 10−5 M ACP, 18 ± % (p < 0.005) of the cells differentiated into macrophages and with 10−4 M the mean percentage of differentiated cells was equivalent to the control values: 5 ± 1% (p < 0.001). Viability of the differentiated and nondifferentiated THP-1 was = 98%.
Substance Class Chemical
Created
by admin
on Tue Oct 22 06:07:27 UTC 2019
Edited
by admin
on Tue Oct 22 06:07:27 UTC 2019
Record UNII
37862HP2OM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACEPROMAZINE MALEATE
GREEN BOOK   MART.   MI   USAN   USP   USP-RS   WHO-DD  
USAN  
Official Name English
ACEPROMAZINE MALEATE [MI]
Common Name English
ACEPROMAZINE MALEATE [GREEN BOOK]
Common Name English
ACEPROMAZINE MALEATE [WHO-DD]
Common Name English
ACEPROMAZINE MALEATE [USP]
Common Name English
NSC-264522
Code English
10-(3-(DIMETHYLAMINO)PROPYL)PHENOTHIAZIN-2-YL METHYL KETONE MALEATE (1:1)
Systematic Name English
ACEPROMAZINE MALEATE [USAN]
Common Name English
ETHANONE, 1-(10-(3-(DIMETHYLAMINO)PROPYL)-10H-PHENOTHIAZIN-2-YL)-, (Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
ACEPROMAZINE MALEATE [USP-RS]
Common Name English
ACEPROMAZINE MALEATE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66883
Created by admin on Tue Oct 22 06:07:27 UTC 2019 , Edited by admin on Tue Oct 22 06:07:27 UTC 2019
Code System Code Type Description
ChEMBL
CHEMBL39560
Created by admin on Tue Oct 22 06:07:27 UTC 2019 , Edited by admin on Tue Oct 22 06:07:27 UTC 2019
PRIMARY
EVMPD
SUB21524
Created by admin on Tue Oct 22 06:07:27 UTC 2019 , Edited by admin on Tue Oct 22 06:07:27 UTC 2019
PRIMARY
NCI_THESAURUS
C76652
Created by admin on Tue Oct 22 06:07:27 UTC 2019 , Edited by admin on Tue Oct 22 06:07:27 UTC 2019
PRIMARY
EPA CompTox
3598-37-6
Created by admin on Tue Oct 22 06:07:27 UTC 2019 , Edited by admin on Tue Oct 22 06:07:27 UTC 2019
PRIMARY
ECHA (EC/EINECS)
222-748-9
Created by admin on Tue Oct 22 06:07:27 UTC 2019 , Edited by admin on Tue Oct 22 06:07:27 UTC 2019
PRIMARY
PUBCHEM
6420038
Created by admin on Tue Oct 22 06:07:27 UTC 2019 , Edited by admin on Tue Oct 22 06:07:27 UTC 2019
PRIMARY
MERCK INDEX
M1303
Created by admin on Tue Oct 22 06:07:27 UTC 2019 , Edited by admin on Tue Oct 22 06:07:27 UTC 2019
PRIMARY Merck Index
CAS
3598-37-6
Created by admin on Tue Oct 22 06:07:27 UTC 2019 , Edited by admin on Tue Oct 22 06:07:27 UTC 2019
PRIMARY
RXCUI
1114057
Created by admin on Tue Oct 22 06:07:27 UTC 2019 , Edited by admin on Tue Oct 22 06:07:27 UTC 2019
PRIMARY RxNorm
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY